Rezolute, Inc. Files 8-K with Exhibits
Ticker: RZLT · Form: 8-K · Filed: Feb 4, 2025 · CIK: 1509261
| Field | Detail |
|---|---|
| Company | Rezolute, Inc. (RZLT) |
| Form Type | 8-K |
| Filed Date | Feb 4, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, exhibits
TL;DR
Rezolute filed an 8-K, likely standard exhibits, check for material updates.
AI Summary
Rezolute, Inc. filed an 8-K on February 4, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as AntriaBio, Inc., is incorporated in Nevada and headquartered in Redwood City, California. This filing does not contain specific financial figures or material events beyond the standard reporting of exhibits.
Why It Matters
This 8-K filing indicates Rezolute, Inc. is providing updated information and exhibits to the SEC, which could include important disclosures for investors.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any immediate negative events or significant financial changes.
Key Players & Entities
- Rezolute, Inc. (company) — Registrant
- AntriaBio, Inc. (company) — Former company name
- February 4, 2025 (date) — Report date
- 275 Shoreline Drive, Suite 500, Redwood City, CA 94065 (location) — Principal Executive Offices
FAQ
What specific exhibits are included in this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific contents of these exhibits are not detailed in the provided text.
What is the primary purpose of this 8-K filing?
The primary purpose is to provide a Regulation FD Disclosure and to report Financial Statements and Exhibits to the SEC.
When was Rezolute, Inc. previously known as?
Rezolute, Inc. was formerly known as AntriaBio, Inc., with a name change date of January 14, 2013.
Where are Rezolute, Inc.'s principal executive offices located?
Rezolute, Inc.'s principal executive offices are located at 275 Shoreline Drive, Suite 500, Redwood City, CA 94065.
What is the fiscal year end for Rezolute, Inc.?
Rezolute, Inc.'s fiscal year ends on June 30.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-02-04 17:11:05
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market
Filing Documents
- tm255467d1_8k.htm (8-K) — 27KB
- tm255467d1_ex99-1.htm (EX-99.1) — 16KB
- 0001104659-25-009180.txt ( ) — 219KB
- rzlt-20250204.xsd (EX-101.SCH) — 3KB
- rzlt-20250204_lab.xml (EX-101.LAB) — 33KB
- rzlt-20250204_pre.xml (EX-101.PRE) — 22KB
- tm255467d1_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On February 4, 2025, Rezolute, Inc. issued a press release to announce outcomes from an independent Data Monitoring Committee (the "DMC") review of the open label arm portion of the sunRIZE Phase 3 study of ersodetug for the treatment of hypoglycemia due to congenital hyperinsulinism and provided additional study updates including guidance on its upcoming interim analysis by the DMC. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated February 4 , 2025 104 Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REZOLUTE, INC. DATE: February 4, 2025 By: /s/ Nevan Charles Elam Nevan Charles Elam Chief Executive Officer